168 related articles for article (PubMed ID: 8677918)
1. The group sequential triangular test for phase II cancer clinical trials.
Bellissant E; Bénichou J; Chastang C
Am J Clin Oncol; 1996 Aug; 19(4):422-30. PubMed ID: 8677918
[TBL] [Abstract][Full Text] [Related]
2. [Design and analysis of phase II trials in oncology with a group sequential method, the triangular test].
Bellissant E; Bénichou J; Chastang C
Therapie; 1991; 46(1):21-7. PubMed ID: 2020920
[TBL] [Abstract][Full Text] [Related]
3. A comparison of methods for phase II cancer clinical trials: advantages of the triangular test, a group sequential method.
Bellissant E; Benichou J; Chastang C
Lung Cancer; 1994 Mar; 10 Suppl 1():S105-15. PubMed ID: 8087499
[TBL] [Abstract][Full Text] [Related]
4. Phase II multi-step planning methods in oncology: comparison, recommendations and potential applications.
Medioni J; de Rycke Y; Tournoux Facon C; Mallet A; Asselain B
Contemp Clin Trials; 2007 May; 28(3):249-57. PubMed ID: 17113357
[TBL] [Abstract][Full Text] [Related]
5. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
6. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
7. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
8. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
9. A microcomputer program for the design and analysis of phase II cancer clinical trials with two group sequential methods, the sequential probability ratio test, and the triangular test.
Bellissant E; Benichou J; Chastang C
Comput Biomed Res; 1994 Feb; 27(1):13-26. PubMed ID: 8004938
[TBL] [Abstract][Full Text] [Related]
10. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
11. Selecting promising treatments in randomized Phase II cancer trials with an active control.
Cheung YK
J Biopharm Stat; 2009; 19(3):494-508. PubMed ID: 19384691
[TBL] [Abstract][Full Text] [Related]
12. Time-to-event analysis with treatment arm selection at interim.
Di Scala L; Glimm E
Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
[TBL] [Abstract][Full Text] [Related]
13. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation.
Thall PF; Estey EH
Stat Med; 1993 Jul; 12(13):1197-211. PubMed ID: 8210822
[TBL] [Abstract][Full Text] [Related]
14. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
15. Alternative designs of phase II trials considering response and toxicity.
Jin H
Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
[TBL] [Abstract][Full Text] [Related]
16. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
17. A modification of Simon's optimal design for phase II trials when the criterion is median sample size.
Hanfelt JJ; Slack RS; Gehan EA
Control Clin Trials; 1999 Dec; 20(6):555-66. PubMed ID: 10588296
[TBL] [Abstract][Full Text] [Related]
18. Response rates, survival, and chemotherapy trials.
Pazdur R
J Natl Cancer Inst; 2000 Oct; 92(19):1552-3. PubMed ID: 11018082
[No Abstract] [Full Text] [Related]
19. Targeting population entering phase III trials: a new stratified adaptive phase II design.
Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
[TBL] [Abstract][Full Text] [Related]
20. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
Huang B; Talukder E; Han L; Kuan PF
J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
